9.62

3.00% +0.28

TriSalus Life Sciences Inc (TLSI)

Overview News Price History Discussions Forecast

TriSalus Life Sciences Inc stock is currently priced at $9.62, with a 24-hour trading volume of 24,438. It has seen a +3.00% increased in the last 24 hours and a -1.64% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $9.40 pivot point. If it approaches the $9.63 resistance level, significant changes may occur.

Previous Close:

$9.34

Open:

$9.35

24h Volume:

24,438

Market Cap:

$289.55M

Revenue:

$15.33M

Net Income/Loss:

$-40.19M

P/E Ratio:

EPS:

Net Cash Flow:

1W Performance:

+2.89%

1M Performance:

-1.64%

6M Performance:

+107.33%

1Y Performance:

+0.00%

1D Range:

$9.35

$9.76

52W Range:

$3.32

$10.42

TriSalus Life Sciences Inc Stock (TLSI) Company Profile

Name

TriSalus Life Sciences Inc

Sector

Healthcare (1213)

Industry

Medical Devices (160)

Phone

888 321 5212

Address

6272 West 91st Avenue, Westminster

Employee

Twitter

Next Earnings Date

Latest SEC Filings

TLSI's Discussions on Twitter

TriSalus Life Sciences Inc Stock (TLSI) Financials Data

TriSalus Life Sciences Inc (TLSI) Revenue 2024

TLSI reported a revenue (TTM) of $15.33 million for the quarter ending September 30, 2023.

TriSalus Life Sciences Inc (TLSI) Net Income 2024

TLSI net income (TTM) was -$40.19 million for the quarter ending September 30, 2023.

TriSalus Life Sciences Inc (TLSI) Earnings per Share 2024

TLSI earnings per share (TTM) was -$1.7522 for the quarter ending September 30, 2023.

TriSalus Life Sciences, Inc., an immunotherapy company that develops and commercializes immunotherapies for the treatment of liver and pancreatic tumors. The company offers the TriNav Infusion System for hepatic arterial infusion of liver tumors; and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. It also develops SD-101, an investigational immunotherapeutic with pressure-enabled drug delivery technology for hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company is based in Westminster, Colorado.